Rohto Pharmaceutical Co., Ltd.

As of March 31, 2026, Rohto Pharmaceutical Co. carries a market capitalization of 3.41B, placing it among publicly traded companies globally. Its enterprise value stands at 3.36B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Rohto Pharmaceutical Co.'s next confirmed earnings release is scheduled for November 12, 2026.

As of March 31, 2026, Rohto Pharmaceutical Co. has 225.96M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Rohto Pharmaceutical Co. maintains a current ratio of 2.04, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

As of the close on October 5, 2026, Rohto Pharmaceutical Co.'s stock has gained approximately 16.82% over the past 52 weeks.

As of March 31, 2026, Rohto Pharmaceutical Co. holds 547.10M in cash and equivalents against 379.65M in total debt, resulting in a net debt position of -213.54M. Total book value stands at 1.90B, with working capital of 768.35M providing operational flexibility.

Rohto Pharmaceutical Co.'s most recent stock split took place on December 29, 2022 with a 1:2 split ratio.